Prognostic significance of angiogenic growth factor serum levels in patients with acute coronary syndromes - PubMed (original) (raw)
Clinical Trial
Prognostic significance of angiogenic growth factor serum levels in patients with acute coronary syndromes
Christopher Heeschen et al. Circulation. 2003.
Abstract
Background: In patients with acute coronary syndromes, compensatory processes are initiated, including angiogenesis and endothelial regeneration of ruptured or eroded plaques. Angiogenic growth factors like vascular endothelial growth factor (VEGF), hepatocyte growth factor (HGF), and basic fibroblast growth factor (bFGF) are upregulated during ischemia. However, it is unknown whether their serum levels are related to clinical outcome.
Methods and results: We measured VEGF, HGF, and bFGF levels in 1090 patients with acute coronary syndromes. Angiographic evaluation was performed at baseline as well as death, and nonfatal myocardial infarctions were recorded during 6-month follow-up. HGF and VEGF, but not bFGF, were significantly and independently associated with the patients' outcome. Patients with elevated VEGF serum levels suffered from adverse outcome (adjusted hazard ratio, 2.50 [1.52 to 4.82]; P=0.002). VEGF elevation was associated with evidence of ischemia and was a significant predictor of the effect of glycoprotein IIb/IIIa inhibition. In contrast, patients with high HGF levels had a significantly lower event rate compared with patients with low HGF levels (adjusted hazard ratio, 0.33 [0.21 to 0.51]; P<0.001). HGF levels did not correlate with evidence of ischemia and did not predict the effect of abciximab. Intriguingly, however, HGF levels significantly correlated with angiographically visible collateralization of the target vessel (22.4% versus 10.5%; P<0.001).
Conclusions: The angiogenic growth factors VEGF and HGF are independent predictors of the patients' prognosis in acute coronary syndromes. Whereas VEGF elevation correlated with the evidence of myocardial ischemia and indicated an adverse outcome, HGF elevation was independent of ischemia and associated with improved collateralization as well as a favorable prognosis.
Similar articles
- Role of circulating vascular endothelial growth factor and hepatocyte growth factor in patients with coronary artery disease.
Soeki T, Tamura Y, Shinohara H, Tanaka H, Bando K, Fukuda N. Soeki T, et al. Heart Vessels. 2000;15(3):105-11. doi: 10.1007/pl00007263. Heart Vessels. 2000. PMID: 11289497 Clinical Trial. - Serum levels of angiogenic cytokines in systemic lupus erythematosus and their correlation with disease activity.
Robak E, Woźniacka A, Sysa-Jedrzejowska A, Stepień H, Robak T. Robak E, et al. Eur Cytokine Netw. 2001 Jul-Sep;12(3):445-52. Eur Cytokine Netw. 2001. PMID: 11566625 Clinical Trial. - Serum levels of the angiogenic cytokines basic fibroblast growth factor (bFGF), vascular endothelial growth factor (VEGF) and hepatocyte growth factor (HGF) in multiple myeloma.
Sezer O, Jakob C, Eucker J, Niemöller K, Gatz F, Wernecke K, Possinger K. Sezer O, et al. Eur J Haematol. 2001 Feb;66(2):83-8. doi: 10.1034/j.1600-0609.2001.00348.x. Eur J Haematol. 2001. PMID: 11168514 - Early use of glycoprotein IIb/IIIa-receptor inhibitors in non-ST-segment-elevation acute coronary syndromes.
Marsh JD. Marsh JD. Am J Health Syst Pharm. 2002 Nov 1;59(21 Suppl 7):S15-26. doi: 10.1093/ajhp/59.suppl_7.S15. Am J Health Syst Pharm. 2002. PMID: 12434711 Review.
Cited by
- Novel hepatocyte growth factor (HGF) binding domains on fibronectin and vitronectin coordinate a distinct and amplified Met-integrin induced signalling pathway in endothelial cells.
Rahman S, Patel Y, Murray J, Patel KV, Sumathipala R, Sobel M, Wijelath ES. Rahman S, et al. BMC Cell Biol. 2005 Feb 17;6(1):8. doi: 10.1186/1471-2121-6-8. BMC Cell Biol. 2005. PMID: 15717924 Free PMC article. - Angiopoietins, Vascular Endothelial Growth Factors and Secretory Phospholipase A2 in Ischemic and Non-Ischemic Heart Failure.
Varricchi G, Loffredo S, Bencivenga L, Ferrara AL, Gambino G, Ferrara N, de Paulis A, Marone G, Rengo G. Varricchi G, et al. J Clin Med. 2020 Jun 19;9(6):1928. doi: 10.3390/jcm9061928. J Clin Med. 2020. PMID: 32575548 Free PMC article. - Complexity in the vascular permeability factor/vascular endothelial growth factor (VPF/VEGF)-receptors signaling.
Mukhopadhyay D, Zeng H, Bhattacharya R. Mukhopadhyay D, et al. Mol Cell Biochem. 2004 Sep;264(1-2):51-61. doi: 10.1023/b:mcbi.0000044374.85095.df. Mol Cell Biochem. 2004. PMID: 15544035 Review. - Impact of percutaneous coronary intervention on biomarker levels in patients in the subacute phase following myocardial infarction: the Occluded Artery Trial (OAT) biomarker ancillary study.
Kruk M, Menon V, Kądziela J, Sadowski Z, Rużyłło W, Janas J, Roik M, Opolski G, Zmudka K, Czunko P, Kurowski M, Busz-Papież B, Zinka E, Jablonski W, Jaworska K, Raczynska A, Skonieczny G, Forman S, Li D, Hochman J. Kruk M, et al. BMC Cardiovasc Disord. 2013 Oct 24;13:91. doi: 10.1186/1471-2261-13-91. BMC Cardiovasc Disord. 2013. PMID: 24156746 Free PMC article. Clinical Trial. - Identification of serum endoglin as a novel prognostic marker after acute myocardial infarction.
Cruz-Gonzalez I, Pabón P, Rodríguez-Barbero A, Martín-Moreiras J, Pericacho M, Sánchez PL, Ramirez V, Sánchez-Ledesma M, Martín-Herrero F, Jiménez-Candil J, Maree AO, Sánchez-Rodríguez A, Martín-Luengo C, López-Novoa JM. Cruz-Gonzalez I, et al. J Cell Mol Med. 2008 Jun;12(3):955-61. doi: 10.1111/j.1582-4934.2008.00156.x. J Cell Mol Med. 2008. PMID: 18494936 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources